Table 2. Peptide-based Vaccines studied in Ovarian Cancer.

Target	MHC-I or MHC-II restricted	Phase	Reference	Clinical Response	Immune Response
HER2/neu	II	I/II	27,28	NA	HER2/neu-specific IgG antibody and T cell responses
NY-ESO-1	both	I	29	NA	NY-ESO-1 specific CD4 and CD8 T cell responses
	I	I	30	3 CR 6 PD	NY-ESO-1 specific CD8 T cell responses
p53	I	II	31	2 NED 12 RD	p53-specific CD8 T cell responses
	n/a	II	32,33	2 SD 18 PD	p53-specific, Th2 dominant CD4 T cell responses
WT-1	I	Case report	34	SD x 1 y	Weak correlation between CA125 and the mononuclear phagocyte/lymphocyte ratio
	I	II	35	1 SD 4 PD 1 NE	NA
STn	II	I	36	3 CR 2 PD 2 NA	Anti-STn Th1 T cell responses
	NA	II	37	Median OS 12.7 mo	Anti-STn IgG and IgM antibody responses, Anti-OSM (ovine submaxillary mucin) antibody responses
Lewisy	NA	I	44	5 NED 19 RD	Anti- Lewisy antibody responses

NA, not available; CR, complete response; PD, progressive disease; n/a, not applicable, NED, no evidence of disease; RD, recurrent disease; SD, stable disease; NE, not evaluable